Back in March 2006, the VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel conducted a review of the Efficacy and Safety of Propoxyphene (aka, Darvon). The study concluded that the group…
found no substantive evidence to alter our previous conclusions about the efficacy and safety of propoxyphene relative to other opioids. Our recommendations on the use of propoxyphene in the Veterans Health Administration remain essentially the same as in the previous review.
In the majority of VA patients with mild to moderate acute pain and who do not have certain characteristics associated with intentional or unintentional overdose, single-dose or short-term therapy with DPP+/-APAP probably provides adequate analgesia with an acceptable safety profile. The efficacy and safety of long-term therapy with DPP+/-APAP for treatment of chronic pain has not been adequately studied. Read the rest of this entry »